PDE9A is an intracellular cyclic guanosine monophosphate (cGMP) hydrolase, which has been exploited as one of the most promising therapeutics for treatment of metabolic diseases, such as diabetes and Alzheimer’s (45), as well as fatigue syndromes (46). The gene discussed is PDE9A; the disease is metabolic disease.